UroGen Pharma (NASDAQ:URGN - Get Free Report) had its price target upped by investment analysts at Scotiabank from $23.00 to $47.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a "sector outperform" rating on the stock. Scotiabank's target price would suggest a potential upside of 290.69% from the company's previous close.
Other equities analysts also recently issued reports about the stock. Oppenheimer reduced their target price on shares of UroGen Pharma from $36.00 to $10.00 and set an "outperform" rating on the stock in a research note on Tuesday, June 3rd. D. Boral Capital reissued a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a research note on Thursday. HC Wainwright downgraded shares of UroGen Pharma from a "buy" rating to a "neutral" rating in a research note on Thursday, May 22nd. Guggenheim boosted their price target on shares of UroGen Pharma from $15.00 to $30.00 and gave the company a "buy" rating in a research note on Friday. Finally, LADENBURG THALM/SH SH started coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price target on the stock. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $28.71.
View Our Latest Analysis on UroGen Pharma
UroGen Pharma Price Performance
Shares of NASDAQ URGN traded up $0.95 during trading on Friday, hitting $12.03. The company had a trading volume of 19,618,047 shares, compared to its average volume of 991,668. The stock has a fifty day simple moving average of $8.54 and a two-hundred day simple moving average of $10.07. UroGen Pharma has a fifty-two week low of $3.42 and a fifty-two week high of $20.70. The firm has a market capitalization of $554.67 million, a price-to-earnings ratio of -3.82 and a beta of 0.40. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The firm had revenue of $20.25 million for the quarter, compared to analyst estimates of $22.71 million. On average, research analysts expect that UroGen Pharma will post -3.12 earnings per share for the current year.
Insiders Place Their Bets
In other UroGen Pharma news, insider Mark Schoenberg sold 5,162 shares of the business's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $7.37, for a total transaction of $38,043.94. Following the completion of the transaction, the insider now owns 153,378 shares in the company, valued at $1,130,395.86. The trade was a 3.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 5.10% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of URGN. RA Capital Management L.P. acquired a new position in shares of UroGen Pharma in the 1st quarter valued at $35,461,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of UroGen Pharma by 216.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company's stock valued at $48,227,000 after buying an additional 2,983,368 shares in the last quarter. Toronto Dominion Bank acquired a new position in shares of UroGen Pharma in the 4th quarter valued at $18,628,000. Acorn Capital Advisors LLC acquired a new position in shares of UroGen Pharma in the 4th quarter valued at $16,149,000. Finally, Nantahala Capital Management LLC acquired a new position in shares of UroGen Pharma in the 4th quarter valued at $14,608,000. Institutional investors and hedge funds own 91.29% of the company's stock.
About UroGen Pharma
(
Get Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
See Also
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
